Original articleSystemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical Study
Section snippets
Patients and Methods
Approval for the SANA Study was obtained from the institutional review board/ethics committee at the University of Miami School of Medicine. The SANA Study will observe patients for at least 1 year after enrollment. Informed consent was obtained from all patients before determination of full eligibility (Table 1), and this research was compliant with the Health Insurance Portability and Accountability Act of 1996. At the start of this study, eligible eyes were designated study eyes, and if both
Baseline Characteristics
A total of 15 patients were initially screened, and 6 patients were excluded from the study for the following reasons: 4 had vision better than 20/40, 1 had uncontrolled hypertension, and 1 had a history of ischemic heart disease. The first 9 patients enrolled in the study had a mean age of 78 years and a median age of 80 years (range, 71–89), with 8 women and 1 man enrolled. All 9 patients completed the 10 visits scheduled for the first 12 weeks of the study. The types of subfoveal neovascular
Patient 1 (Figures 6–8)
An 89-year-old woman was complaining of vision loss in her left eye (study eye) after a single treatment with PDT. Three months after PDT, she was diagnosed with a large submacular hemorrhage in association with leakage from subfoveal occult CNV (study eye; Figs 6A, 7A, 8A). The lesion in the right eye (fellow eye) was diagnosed as a fibrotic scar with an area of active CNV in the temporal macula. At baseline, BCVAs were 20/80+1 in the study eye and 20/500 in the fellow eye. Central retinal
Discussion
After 3 months, the results from the SANA Study are promising but also very preliminary. In this first cohort of 9 patients receiving 2 or 3 infusions of bevacizumab at a dose of 5mg/kg, systemic bevacizumab was associated with a significant increase in VA and a significant decrease in central retinal thickness as early as 1 week after initiation of therapy. This overall improvement continued through week 12 of the study. Because 8 of the 9 patients had evidence of CNV in both eyes, we expected
References (45)
- et al.
The epidemiology of age-related macular degeneration
Am J Ophthalmol
(2004) - et al.
Pathogenesis of lesions in late age-related macular disease
Am J Ophthalmol
(2004) - et al.
Classification of choroidal neovascularization by digital indocyanine green videoangiography
Ophthalmology
(1996) - et al.
Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization
Ophthalmology
(2003) - et al.
Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes
Am J Ophthalmol
(1996) - et al.
Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes
Microvasc Res
(2002) - et al.
Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
Am J Pathol
(1999) - et al.
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection
Ophthalmology
(2003) Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer
Cancer Treat Rev
(2004)- et al.
Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillarisEvidence for a trophic paracrine relation
Am J Pathol
(1999)
Potential public health impact of age-related eye disease study resultsAreds report no. 11
Arch Ophthalmol
Causes and prevalence of visual impairment among adults in the United States
Arch Ophthalmol
The prevalence of age-related macular degeneration in the United States
Arch Ophthalmol
Retinal angiomatous proliferation in age-related macular degeneration
Retina
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfinfluorescein angiographic guidelines for evaluation and treatment—TAP and VIP report no. 2
Arch Ophthalmol
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfinone-year results of 2 randomized clinical trials—TAP report 1
Arch Ophthalmol
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfintwo-year results of 2 randomized clinical trials—TAP report 2
Arch Ophthalmol
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degenerationtwo-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2
Am J Ophthalmol
Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes
Retina
Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration
Br J Ophthalmol
Ocular angiogenesistranslating preclinical indications to successful clinical development
Expert Opin Ther Targets
Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
Invest Ophthalmol Vis Sci
Cited by (0)
Manuscript no. 2004-422.
Supported by the Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida; an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York; National Institutes of Health, Bethesda, Maryland (center grant no.: P30 EY14801); and the German Research Foundation, Bonn, Germany.
No financial support was received from Genentech, Inc. to perform this clinical study, and no support was received for scientific presentations at meetings and travel expenses related to this clinical study. All potential conflicts of interest relate to competing drugs and pharmaceutical companies. Dr Rosenfeld has received competing clinical research grants from Genentech, Inc.; Eyetech Pharmaceuticals; QLT, Inc.; Novartis Ophthalmics; and Alcon Laboratories. Drs Rosenfeld and Puliafito have indicated support for competing scientific presentations at meetings and reimbursement for travel expenses. Drs Rosenfeld, Puliafito, and Michels have participated in competing scientific advisory boards and have received honoraria and reimbursement for travel expenses. Dr Rosenfeld has served on a speaker’s bureau for Novartis Ophthalmics. Dr Puliafito is designated on a patent for optical coherence tomography and receives royalties.
Reprint requests to Philip J. Rosenfeld, MD, PhD, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136.
- 1
Dr Michels is currently affiliated with University Eye Hospital Vienna, Vienna, Austria.